Brief: CSPC Pharmaceutical Says Phase III Study Of Anbenitamab With Docetaxel Meets Primary Endpoint
31/03/2026 14:38
March 31 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK: PHASE III STUDY OF ANBENITAMAB WITH DOCETAXEL FOR HER2+ BREAST CANCER MEETS PRIMARY ENDPOINT Further company coverage: 1093.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines